OncoMatch/Clinical Trials/NCT05450965
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Is NCT05450965 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Onvansertib for small-cell lung cancer.
Treatment: Onvansertib — This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — frontline
Lab requirements
Blood counts
normal organ and marrow function as pre-defined
Kidney function
normal organ and marrow function as pre-defined
Liver function
normal organ and marrow function as pre-defined
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Maryland Greenebaum Comprehensive Cancer Center · Baltimore, Maryland
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify